Sara K. Silbert, M.D., M.H.Sc
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 1W5890
- Bethesda, MD 20892
- (240) 858-3666
- sara.silbert@nih.gov
RESEARCH SUMMARY
Dr. Silbert is a pediatric oncologist in the Hematologic Malignancies Section. As a dually boarded oncologist and palliative medicine physician, her clinical and research interests lie at the intersection of furthering novel immunotherapies for pediatric cancers and optimizing patient quality of life. Her clinical focus is on the treatment of children and young adults with relapsed/refractory hematologic malignancies using early phase chimeric antigen receptor (CAR) T cell therapies. Additional interests include the measure and management of CAR toxicities and the integration of palliative care into early phase oncology trials.
Areas of Expertise
Information for Patients
Learn more about the Leukemia, Lymphoma, Transplant and Cell Therapy Team and clinical trials
Sara K. Silbert, M.D., M.H.Sc
Research
Dr. Silbert focuses on translation of chimeric antigen receptor therapy to treat high-risk hematologic malignancies in pediatric patients. She also works closely with the pediatric psychosocial care team and the pain and palliative care service to conduct research to optimize patient quality of life.
Publications
Biography
Sara K. Silbert, M.D., M.H.Sc
Dr. Silbert received her medical degree in 2015 from Tulane University School of Medicine. In 2018, she completed her pediatric residency in Chicago at McGaw Medical Center of Northwestern University Pediatric Residency Program, after which she completed a fellowship in Hospice and Palliative Medicine at the University of Michigan. Following this, she completed fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington DC in 2022. From 2022-2023, she joined the Hematologic Malignancies Section of the Pediatric Oncology Branch as an advanced studies fellow with a focus on immunotherapy, particularly early phase CAR T-cell therapy.